RxDoctor Payments Data

Jennifer Rosics, PA

Medical · Casper, WYNPI 1356572580

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.8% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boston Scientific accounts for 82.9% of it on its own, with 6 other manufacturers making up the rest.

$2,709in general payments, 2019–2025

Across 121 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • AbbVie$157
  • Merz Pharmaceuticals, LLC$124
  • Biohaven Pharmaceutical Holding Company Ltd.$76
  • Collegium Pharmaceutical, Inc.$68
  • Hikma Pharmaceuticals USA$21
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$2,59596%
  • Education$1144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,709 in reported general payments places this provider in the 85th percentile of 56 medical providers in Wyoming.

See all medical providers in Wyoming

Medicare billing

Part B allowed, 2024
$143,158
Medicare patients
92
Services billed
11,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate58$26,243
OxycontinOxycodone Hcl28$16,669
BelsomraSuvorexant24$10,334
Topiramate ErTopiramate12$8,330
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen223$6,692
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl56$6,485
Tramadol Hcl ErTramadol Hcl54$4,995
Fentanyl28$4,399
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen148$3,975
Gabapentin231$3,786
Oxycodone Hcl163$3,126
Lidocaine13$2,361
Pregabalin129$2,082
Buprenorphine Hcl60$1,947
Celecoxib61$1,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$68$26,24358 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl, Morphine Sulfate$21$9,000145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 56 medical providers in Wyoming.

Other medical in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →